RECEIV

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with First Class Postage to the U.S. Postal Service to the Assistant Commissioner for Patents, U.S. Patent and Trademark Office, Washington, D.C. 20231 on the date indicated

Date 503

Christine Ferraro

Box Non-Fee Amendmen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Glucksmann et al.

Serial No.: 09/970,287

Confirmation No.: 9083

Filed: October 3, 2001

For: 22437, A Novel Human Sulfatase

and Uses Therefor

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is being filed before the first Office Action on the merits

A copy of each of the references listed on the two attached Forms PTO/SB/08 is enclosed herewith and forms a part hereof. Consideration of each of the references cited herein is respectfully requested.

A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

WO 99/63088 is a very large document and is submitted on a CD-ROM.

No additional fee is believed to be due. However, the Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account No. <u>04-1679</u>.

Respectfully submitted,

Group Art Unit: 1645

Examiner: Not Yet Assigned

Attorney Docket No.: E0596-00014

28 February 2003

Bv.

M.A. GLUCKSMANN ET AL.

Gary D. Colby, Ph.D., J.D.

Registration No. 40,961 DUANE MORRIS LLP

One Liberty Place

Philadelphia, PA 19103-7396

Telephone: 215-979-1000 Direct Dial: 215-979-1849 Facsimile: 215-979-1020

PH1\1065701.1

# 4/ Suppl.

PTO/SB/08A (02-03)

Sheet 1

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known			
Application Number	09/970,287		
Filing Date	October 3, 2001		
First Named Inventor	Glucksmann		
Art Unit	1645		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	E0596-00014		

			U. S. PATENT D		
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (thno wn)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages,C olumns, Lines, Where Relevant Passages or Relevant Figures Appear
· · · · · · ·		US-			3
		08-			
		US-			
		US-			• • •
		US-			
**		US-			
		US-			
		US-		**************************************	T 71
		US-			
		US-			T SA O
		US-			E O M
		US-			9 1 9
		US-			
		US-			
	ļ	US-			123
		US-		W + ≠ W   0.	2900
		US-			
		US-			
	<b></b>	US-			
	<del>                                     </del>	US-			

,		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign PatentD ocument	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		WO 01/55411 A2	08-02-2001	Millennium Pharmaceuticals, Inc.		
		WO 99/63088 A	12-09-1999	Gerentech, Inc.		
		1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -				<u> </u>
	-					<u> </u>
	-					<u></u>
	<u> </u>			1		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D C 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08B (02-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitut	e for form 1449/P	10		Application Number	09/970,287	
INFO	DRMATIC	ON DIS	CLOSURE	Filing Date	October 3, 2001	
STATEMENT BY APPLICANT		First Named Inventor	Glucksmann			
				Art Unit	1645	
	(Use as many	/ sheets as n	ecessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	E0596-00014	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appro the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), number(s), publisher, city and/or country where published.	priate), title of volume-issue	T <sup>2</sup>
		STEIN ET AL., 1989, J. Biol. Chem., 264(23):13865-13872	TECH	I
		GENBANK ® Database Accession No. AB033073, 17 May 2001	CENTE	
		NAGASE ET AL., 1999, DNA Res. 6:337-345 (abstract only)	TECH CENTER 1600/2900	0000
			12900	
				-

Examiner	Date	
Signature	Considere	d

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.